TopiVert to Present TOP1630 Clinical Proof-of-Concept Data in Dry Eye Syndrome at the ARVO 2018 Annual Meeting TopiVert to Present TOP1630 Clinical Proof-of-Concept Data in Dry Eye Syndrome at the ARVO 2018 Annual Meeting London, UK, 23 April 2018: TopiVert Pharma Ltd ("TopiVert" or the "Company"), a...

TopiVert Publication Highlights the Potential of Narrow Spectrum Kinase Inhibitors in Dry Eye Disease and Supports Successful Clinical Proof-Of-Concept Study with TOP1630 TopiVert Publication Highlights the Potential of Narrow Spectrum Kinase Inhibitors in Dry Eye Disease and Supports Successful Clinical Proof-Of-Concept Study with TOP1630 London, UK, 22 March...